Carl Byrnes
Stock Analyst at Northland Capital Markets
(1.33)
# 3,290
Out of 4,829 analysts
23
Total ratings
37.5%
Success rate
-0.37%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLFS BioLife Solutions | Maintains: Outperform | $28 → $31 | $23.29 | +33.10% | 2 | Jan 8, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Outperform | $13 | $5.02 | +149.00% | 1 | Oct 25, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $11 → $13 | $8.71 | +43.51% | 3 | Oct 3, 2024 | |
| MDAI Spectral AI | Initiates: Outperform | $6 | $1.24 | +383.87% | 1 | Aug 12, 2024 | |
| COCH Envoy Medical | Initiates: Outperform | n/a | $1.69 | - | 1 | Dec 21, 2023 | |
| AMRN Amarin Corporation | Maintains: Market Perform | $40 → $25 | $10.38 | +140.85% | 1 | Jul 19, 2023 | |
| CDIO Cardio Diagnostics Holdings | Initiates: Outperform | $8 | $0.19 | +4,221.99% | 1 | May 22, 2023 | |
| VTVT vTv Therapeutics | Maintains: Outperform | $60 → $80 | $20.80 | +284.62% | 4 | Aug 17, 2022 | |
| MDXG MiMedx Group | Initiates: Outperform | $23 | $7.05 | +226.24% | 3 | Jul 26, 2021 | |
| ESPR Esperion Therapeutics | Maintains: Market Perform | $30 → $24 | $0.80 | +2,906.77% | 4 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $2,000 | $1.26 | +158,630.16% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.11 | - | 1 | Sep 27, 2017 |
BioLife Solutions
Jan 8, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $23.29
Upside: +33.10%
TriSalus Life Sciences
Oct 25, 2024
Initiates: Outperform
Price Target: $13
Current: $5.02
Upside: +149.00%
BrainsWay
Oct 3, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $8.71
Upside: +43.51%
Spectral AI
Aug 12, 2024
Initiates: Outperform
Price Target: $6
Current: $1.24
Upside: +383.87%
Envoy Medical
Dec 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $1.69
Upside: -
Amarin Corporation
Jul 19, 2023
Maintains: Market Perform
Price Target: $40 → $25
Current: $10.38
Upside: +140.85%
Cardio Diagnostics Holdings
May 22, 2023
Initiates: Outperform
Price Target: $8
Current: $0.19
Upside: +4,221.99%
vTv Therapeutics
Aug 17, 2022
Maintains: Outperform
Price Target: $60 → $80
Current: $20.80
Upside: +284.62%
MiMedx Group
Jul 26, 2021
Initiates: Outperform
Price Target: $23
Current: $7.05
Upside: +226.24%
Esperion Therapeutics
May 5, 2021
Maintains: Market Perform
Price Target: $30 → $24
Current: $0.80
Upside: +2,906.77%
Oct 22, 2018
Initiates: Outperform
Price Target: $2,000
Current: $1.26
Upside: +158,630.16%
Sep 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $2.11
Upside: -